| COBS | cesarean-obtained barrier-sustained; chronic organic brain syndrome |
|---|---|
| MSV | maximum sustained level of ventilation; mean scale value; mean spatial velocity; Moloney sarcoma vir... |
| MSVC | maximal sustained ventilatory capacity |
| SA | salicylic acid; saline [solution]; salt added; sarcoidosis; sarcoma; scalenus anticus; secondary ame... |
| SDS | same day surgery; school dental services; self-rating depression scale; sensory deprivation syndrome... |
| orphan drugs | Drugs, biologicals, and medical devices (including diagnostic in vitro tests) that may be useful in common or rare diseases but which are not considered commercially viable. Synonym: orphan drugs. (05 Mar 2000) |
|---|---|
| carpal tunnel release | <orthopaedics, procedure> An orthopaedic surgical procedure which relieves the pressure exerted on the median nerve within the carpal tunnel in the wrist. This surgery may be performed conventionally via a small incision or using a fibreoptic scope (endoscopic carpal tunnel repair). (08 Jan 1998) |
| Release | <chemical> Abscission agent for loosening citrus fruit before harvesting Synonym: 5-chloro-3-methyl-4-nitro-1h-pyrazole (26 Jun 1999) |
| release factor | A component of the specialised transport system involved in the transport of cobalamin (vitamin B12) across the wall of the intestine. Dissociates the complex between cobalamin and the extracellular cobalamin binding glycoprotein known as intrinsic factor. (18 Nov 1997) |
| release phenomenon | The increased tonus and hyperirritability of muscle-stretch reflexes which occur following damage of the upper portions of the extrapyramidal system. (05 Mar 2000) |
| melanotropin release-inhibiting hormone | Inhibits synthesis and release of melanotropin. Synonym: melanotropin release-inhibiting hormone. Origin: melanotropin + G. States, stationary, + -in (05 Mar 2000) |
| ryanodine receptor calcium release channel | Protein complexes that mediate the release of calcium from the sarcoplasmic reticulum in both skeletal and cardiac muscle cells by forming tetrametric complexes. These complexes each then act as a calcium channel. There are three isoforms of the ryr: ryr1, ryr2, and ryr3. Ryr1 is specifically expressed in skeletal muscles and ryr2 in cardiac muscles. Ryr3 is yet another isoform found in non-muscle cells such as neuronal cells. (12 Dec 1998) |
| pituitary hormone release inhibiting hormones | Polypeptide hormones produced in the hypothalamus which inhibit the release of pituitary hormones. (12 Dec 1998) |
| msh release-inhibiting hormone | <chemical> An oligopeptide hormone produced in the hypothalamus that inhibits the release of melanocyte-stimulating hormone (msh). Chemical name: Melanostatin (12 Dec 1998) |
| control release suture | Eyeless suture with thread attached to needle such that the two separate when tension is applied to the thread. (05 Mar 2000) |
| prolactin release-inhibiting hormone | <chemical> A polypeptide hormone produced in the hypothalamus that inhibits the release of prolactin. Chemical name: Prolactin release-inhibiting factor (12 Dec 1998) |
| histamine release | The secretion of histamine from mast cell and basophil granules by exocytosis. This can be initiated by a number of factors, all of which involve binding of IgE, cross-linked by antigen, to the mast cell or basophil's fc receptors. Once released, histamine binds to a number of different target cell receptors and exerts a wide variety of effects. (12 Dec 1998) |
| somatotropin release-inhibiting factor | <protein> Gastrointestinal and hypothalmic peptide hormone (two forms: 14 and 28 residues), found in gastric mucosa, pancreatic islets, nerves of the gastrointestinal tract, in posterior pituitary and in the central nervous system. Inhibits gastric secretion and motility: in hypothalamus/pituitary inhibits somatotropin release. (18 Nov 1997) |
| somatotropin release-inhibiting hormone | <protein> Gastrointestinal and hypothalmic peptide hormone (two forms: 14 and 28 residues), found in gastric mucosa, pancreatic islets, nerves of the gastrointestinal tract, in posterior pituitary and in the central nervous system. Inhibits gastric secretion and motility: in hypothalamus/pituitary inhibits somatotropin release. (18 Nov 1997) |
| deliberate release | Generally refers to putting a genetically manipulated organism into field trials. (14 Nov 1997) |